# EDGAR Filing Document

**Accession Number:** 0001444307
**File Stem:** 0000000000-23-001400
**Filing Date:** 2023-2
**Character Count:** 2742
**Document Hash:** 35a1d7f68eda589bcc05b43475f92e5c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-23-001400.hdr.sgml**: 20230313

**ACCESSION NUMBER**: 0000000000-23-001400

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230210

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ONCOSEC MEDICAL Inc
- **CENTRAL INDEX KEY:** 0001444307
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 980573252
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 0731

**FILING VALUES:**
- **FORM TYPE:** UPLOAD

**BUSINESS ADDRESS:**
- **STREET 1:** 820 BEAR TAVERN ROAD
- **CITY:** EWING
- **STATE:** NJ
- **ZIP:** 08628
- **BUSINESS PHONE:** (858) 210-7333

**MAIL ADDRESS:**
- **STREET 1:** 820 BEAR TAVERN ROAD
- **CITY:** EWING
- **STATE:** NJ
- **ZIP:** 08628

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NetVentory Solutions, Inc.
- **DATE OF NAME CHANGE:** 20080902

## Text-Extract

```

United States securities and exchange commission logo

                      February 10, 2023

       Robert Arch, Ph.D.
       Chief Executive Officer
       OncoSec Medical Inc.
       24 North Main Street
       Pennington, NJ 08534

                                                        Re: OncoSec Medical
Inc.
                                                            Form 10-K for
Fiscal Year Ended July 31, 2022
                                                            Filed October 31,
2022
                                                            File No. 000-54318

       Dear Robert Arch:

              We have completed our review of your filing. We remind you that
the company and its
       management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding
       any review, comments, action or absence of action by the staff.

                      Sincerely,

                      Division of Corporation Finance

                      Office of Life Sciences

```

### Attached PDF Documents

**Attachment 1:** `filename1`

![img-0.jpeg](img-0.jpeg)

DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

February 10, 2023

Robert Arch, Ph.D.
Chief Executive Officer
OncoSec Medical Inc.
24 North Main Street
Pennington, NJ 08534

**Re: OncoSec Medical Inc.**
**Form 10-K for Fiscal Year Ended July 31, 2022**
**Filed October 31, 2022**
**File No. 000-54318**

Dear Robert Arch:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance
Office of Life Sciences